Lung and head-and-neck cancer

Lung, head-and-neck cancers are devastating for patients and their families. But there’s hope, and we are committed to bringing new treatments and cutting-edge scientific advancements to patients in need.

Our specialists support the whole range of clinical studies from early phase to Phase III (registry studies), as well as post-approval safety trials. Our team has wide experience as medical leads in different indications (adjuvant, neoadjuvant,  chemo-radiation, and in metastatic settings) and with different investigational compounds (targeted agents, checkpoint inhibitors, monoclonal antibodies, viral vectors, and chemotherapy). Our colleagues are based in Europe, North America, and the APAC region, providing a global presence for high-quality medical oversight and monitoring.

A Phase III study for non-small-cell lung cancer (NSCLC) in Europe and Asia-Pacific offers a good example of our work. In this case, we faced competition for patients and investigators from a high number of sites involved in similar studies. Site selection was limited by the complexity of the required EGFR mutation lab test.

After establishing lab-test capabilities, we targeted hospitals and academic centers that had access to an eligible study population and experienced, scientifically motivated investigators. Patient education and consent tools supported enrollment and retention. The trial ultimately involved 700+ patients in 100+ sites covering 14 countries, including Korea, Taiwan, and Thailand. Local import/export license requirements were ably managed by our Integrated Clinical Trial Supply & Logistics team. The result: Last-patient-first-visit was completed four months ahead of schedule, while on-time database lock enabled regulatory submission and approval.

In the past 5 years, we have worked on nearly 100 clinical lung cancer and head and neck cancer projects, including NSCLC, small cell lung cancer, and malignant mesothelioma trials.